HALOZYME THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.57 USD | +0.29% |
|
-0.18% | +4.36% |
Presentation Operator MessageOperator (Operator)Hello, and welcome to the Halozyme Fourth Quar...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Companyâs ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
Calendar
2024-05-07
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
38.57
USD
Average target price
50.5
USD
Spread / Average Target
+30.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.36% | 4.9B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Transcript : Halozyme Therapeutics, Inc., Q4 2023 Earnings Call, Feb 20, 2024
